Mural Oncology plc (MURA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
10 EARLSFORT TERRACE DUBLIN 2, D02 T380 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 270,852,000 | |||
| Cash and cash equivalent | 270,852,000 | |||
| Receivables | 5,548,000 | |||
| Prepaid expense | 150,000 | |||
| Deferred costs | ||||
| Other current assets | 787,000 | |||
| Other undisclosed current assets | ||||
| Total current assets: | 277,337,000 | |||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 12,747,000 | |||
| Property, plant and equipment | 11,403,000 | |||
| Restricted cash and investments | 258,000 | |||
| Other noncurrent assets | ||||
| Total noncurrent assets: | 24,408,000 | |||
| TOTAL ASSETS: | 301,745,000 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 22,919,000 | |||
| Accounts payable | 5,973,000 | |||
| Accrued liabilities | 16,946,000 | |||
| Other liabilities | ||||
| Other undisclosed current liabilities | 6,098,000 | |||
| Total current liabilities: | 29,017,000 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 8,911,000 | |||
| Other liabilities | ||||
| Operating lease, liability | 8,911,000 | |||
| Total noncurrent liabilities: | 8,911,000 | |||
| Total liabilities: | 37,928,000 | |||
| Equity | ||||
| Equity, attributable to parent, including: | 263,817,000 | |||
| Common stock | 167,000 | |||
| Additional paid in capital | 294,507,000 | |||
| Accumulated deficit | (30,857,000) | |||
| Other undisclosed equity, attributable to parent | ||||
| Total equity: | 263,817,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 301,745,000 | |||
Income Statement (P&L) (USD)
| 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|
| Operating expenses | (196,238,000) | ||
| Operating loss: | (196,238,000) | ||
| Nonoperating income (Other Nonoperating income) | 951,000 | ||
| Loss from continuing operations before income taxes: | (195,287,000) | ||
| Income tax expense | (12,160,000) | ||
| Net loss available to common stockholders, diluted: | (207,447,000) | ||
Comprehensive Income (USD)
| 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|
| Net loss: | (207,447,000) | ||
| Other comprehensive income | |||
| Comprehensive loss, net of tax, attributable to parent: | (207,447,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.